Drug Profile
BMS 903452
Alternative Names: BMS-903452Latest Information Update: 02 May 2016
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Class Antihyperglycaemics
- Mechanism of Action GPR119 protein agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 02 May 2016 Chemical structure information added
- 26 Apr 2016 No recent reports on development identified - Phase-I for Type-2 diabetes mellitus in USA (PO, liquid & suspension)
- 14 Mar 2012 Bristol-Myers Squibb completes its phase I trial for Type-2 diabetes mellitus in USA (NCT01240980)